Summary: An alpha1 adrenergic agonist shows preclinical efficacy in a preclinical model for dry eye syndrome
Abstract
Trabodenoson, an alpha1 adrenergic agonist, shows preclinical efficacy in a preclinical model for dry eye syndrome, according to a study co-authored by Experimentica Ltd
According to the results of a study published in the June 2018 issue of Investigative Ophthalmology and Vision Research, trabodenoson eye drops reduced attenuated hallmark signs of dry-eye disease pathology, including corneal surface inflammation, lacrimal gland infiltration by immune cells and loss of mucin-producing goblet cells in the conjunctiva.
The study, conducted in collaboration with Inotek Pharmaceuticals Corp., K&P Scientific LLC and Loyola University Chicago, compared the preclinical efficacy with a marketed formulation of ophthalmic cyclosporine emulsion and concluded that trabodenoson showed similar or better preclinical efficacy, supporting the development of A1R-targeting pharmaceuticals for DED.
Experimentica Ltd. is a global contract research organization specialized in ocular models. Headquartered in Kuopio, Finland, Experimentica Ltd. focuses on Advancing Ophthalmic Drug DiscoveryTM by offering an industry-leading portfolio for ophthalmic drug development.
Contact for media enquiries:
Dr. Simon Kaja
Chief Scientific Officer
Experimentica Ltd.
Phone: +1 (844) 393-49393
Email: kaja@experimentica.com